Rainbow Children's Medicare Limited
₹1,217.55+₹19.55 (+1.6%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹12,756 Cr
- P/E
- 51.8x
- EV / EBITDA
- 29.5x
- Revenue
- ₹1,455 Cr
- Net margin
- 17.4%
- ROCE
- 20.6%
Price chart
Technical chartScreen technicals →-11.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -7.4%
- 3M
- -19.7%
- 6M
- -2.9%
- 1Y
- -11.8%
- 5Y
- +166.9%
52-week range
Day change +₹19.55 (+1.6%) from ₹1,198 to ₹1,218 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in RAINBOW, bought on each weekday since 2022.
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 24.8%
Concerns1
- Operating margin declining for 3 consecutive years (35.0% → 34.0% → 33.0%)
Rule-based from financial data. Not advice.
About the company
Rainbow Children's Medicare Limited operates a multi-specialty paediatric, obstetrics, and gynaecology hospital chain in India. The company offers medical and healthcare services to children and women.
Read moreShow less
Rainbow Children's Medicare Limited operates a multi-specialty paediatric, obstetrics, and gynaecology hospital chain in India. The company offers medical and healthcare services to children and women. It also provides pediatric services under brand Rainbow Children's Hospital which include newborn and pediatric intensive care; pediatric multi-specialty services; and pediatric quaternary care, such as multi-organ transplantation. In addition, the company offers women care services under Birthright brand that comprise perinatal care services, such as routine and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility support, and a range of gynecology treatments, as well as operates private pediatric DNB (Diplomate of National Board) training program offering postgraduate and fellowship opportunities to train future healthcare professionals. Rainbow Children's Medicare Limited was incorporated in 1998 and is based in Hyderabad, India.
- Sector
- Healthcare
- Shares outstanding
- 10.1 Cr shares
- ISIN
- INE961O01016
- BSE code
- 543524
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹12,756 Cr
- P/E
- 51.8x
- P/B
- 8.1x
- EV / EBITDA
- 29.5x
- EV / Sales
- 10.8x
- P/S
- 10.3x
- Earnings yield
- 1.9%
- 52-week high
- ₹1,597.65
- 52-week low
- ₹1,106.05
Profitability
- Operating margin
- 33.7%
- Net margin
- 17.4%
- EBITDA margin
- 36.7%
- ROE
- 16.7%
- ROCE
- 20.6%
- ROA
- 10.0%
- Dividend payout
- 14.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 12.8%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,455 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 17.6%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.2%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹454 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.2%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.7%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 24.8%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹306 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -2.9%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹9.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 22.2%
Solvency and efficiency
- Current ratio
- 7.02
- Debt / Equity
- 0.57
- Debt / Assets
- 0.34
- Debt / EBITDA
- 1.62
- Interest coverage
- 7.07
- Financial leverage
- 1.67
- CFO / Net profit
- 1.42
- Cash / Market cap
- 4.4%
- Cash per share
- ₹55.77
- Asset turnover
- 0.58
- Fixed asset turnover
- 1.01
- Capital intensity
- 0.99
- Debtor days
- 21 days
- Inventory turnover
- 7.02
- Cash conversion cycle
- -104 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹16 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹976 Cr |
| Sales | Operating profit | ₹479 Cr |
| Operating profit | Interest | ₹74 Cr |
| Operating profit | Depreciation | ₹132 Cr |
| Operating profit | Profit before tax | ₹273 Cr |
| Other income | Profit before tax | ₹49 Cr |
| Profit before tax | Tax and other | ₹84 Cr |
| Profit before tax | Net profit | ₹238 Cr |
Revenue and net profit
Revenue grew 17.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹614 Cr | ₹49 Cr |
| FY2022 | ₹925 Cr | ₹142 Cr |
| FY2023 | ₹1,114 Cr | ₹206 Cr |
| FY2024 | ₹1,237 Cr | ₹215 Cr |
| FY2025 | ₹1,455 Cr | ₹238 Cr |
Cash flows
FY2025: ₹385 Cr from operations, ₹122 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹142 Cr | ₹55 Cr |
| FY2022 | ₹214 Cr | ₹45 Cr |
| FY2023 | ₹315 Cr | -₹145 Cr |
| FY2024 | ₹306 Cr | ₹92 Cr |
| FY2025 | ₹385 Cr | ₹122 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,455 Cr+17.6%1Y
- Net profit
- ₹238 Cr+10.7%1Y
- Cash from operations
- ₹385 Cr
- Free cash flow
- ₹122 Cr+32.6%1Y
- Revenue CAGR, 5Y
- 12.2%
- EBITDA CAGR, 5Y
- 15.5%
- Net profit CAGR, 5Y
- 24.8%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,455 Cr | ₹479 Cr | — | ₹238 Cr | ₹385 Cr | ₹122 Cr | 16.0% | +17.6% | +10.7% |
Monthly returns
Month-by-month returns of RAINBOW across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,354 Cr |
| Equity capital | ₹102 Cr |
| Reserves | ₹1,387 Cr |
| Borrowings | ₹734 Cr |
| Other liabilities | ₹131 Cr |
| Assets | ₹2,354 Cr |
| Fixed assets | ₹1,368 Cr |
| Capital work in progress | ₹28 Cr |
| Investments | ₹596 Cr |
| Other assets | ₹362 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
RAINBOW trades at 51.8x earnings against a peer median of 52.6x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Rainbow Children's Medicare LimitedRAINBOWthis company | ₹12,756 Cr | 51.8x | 8.1x | 16.7% | 29.5x |
| ALEMBIC PHARMACEUTICALS LIMITEDAPLLTD | ₹15,765 Cr | 35.5x | 3.0x | 13.6% | 15.2x |
| Natco Pharma Ltd.NATCOPHARM | ₹15,582 Cr | 10.3x | 1.9x | 23.4% | 8.8x |
| Granules India Ltd.GRANULES | ₹14,372 Cr | 39.7x | 4.0x | 14.0% | 18.5x |
| ACUTAAS CHEMICALS LIMITEDACUTAAS | ₹13,806 Cr | 61.2x | 9.7x | 6.5% | 154.5x |
| Caplin Point Laboratories Ltd.CAPLIPOINT | ₹13,763 Cr | 39.4x | 7.5x | — | — |
| RUBICON RESEARCH LIMITEDRUBICON | ₹11,141 Cr | 65.0x | — | 5.0% | 115.2x |
| ALIVUS LIFE SCIENCES LIMITEDALIVUS | ₹10,777 Cr | 20.3x | 3.6x | 20.2% | 15.2x |
| Vijaya Diagnostic Centre LimitedVIJAYA | ₹10,297 Cr | 69.2x | 12.1x | 17.6% | 45.6x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
RAINBOW since 1 January, against earlier years.
Historical volatility
RAINBOW's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 27.0% |
| FY2022 | 32.0% |
| FY2023 | 35.0% |
| FY2024 | 34.0% |
| FY2025 | 33.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,455 Cr |
| Costs | |
| Interest | ₹74 Cr |
| Expenses | ₹976 Cr |
| Operating profitOperating Profit | ₹479 Cr |
| Other income and charges | |
| Profit before tax | ₹322 Cr |
| Tax | |
| Net profitNet Profit | ₹238 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,354 Cr |
| Equity capitalEquity Capital | ₹102 Cr |
| Reserves | ₹1,387 Cr |
| Borrowings | ₹734 Cr |
| Other liabilitiesOther Liabilities | ₹131 Cr |
| AssetsTotal Assets | ₹2,354 Cr |
| Fixed assetsFixed Assets | ₹1,368 Cr |
| Capital work in progressCWIP | ₹28 Cr |
| Investments | ₹596 Cr |
| Other assetsOther Assets | ₹362 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹385 Cr |
| Investing cash flowCash from Investing Activity | -₹263 Cr |
| Financing cash flowCash from Financing Activity | -₹113 Cr |
| Change in cashNet Cash Flow | ₹9 Cr |
Learn while you research
Academy chapters picked for Rainbow Children's Medicare Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 51.8, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read